
It's been a sluggish year for Toronto real estate — so why have these home stagers never done better?Global Travel and Expense T amp E Software Market Size, Share and Forecast By Key Players-Oracle Corporation, Apptricity Corp., SAP SE (Concur), Basware, Expensify
Victory Day An Inspiration for the world(All times Eastern) Schedule subject to change and/or blackouts Sunday, Dec. 15 COLLEGE BASKETBALL (MEN’S) 1 p.m. CBSSN — Omaha at Iowa St. 2 p.m. BTN — New Orleans at Iowa 4 p.m. BTN — Georgia Tech vs. Northwestern, Milwaukee 6 p.m. BTN — Stephen F. Austin at Oregon 8 p.m. BTN — Montana St. at Southern Cal COLLEGE BASKETBALL (WOMEN’S) Noon ACCN — Miami at Pittsburgh BTN — Iowa at Michigan St. SECN — Longwood at Florida 1 p.m. ABC — NC State at Louisville 2 p.m. ACCN — Georgia Tech at North Carolina ESPN2 — West Virginia at Temple SECN — South Florida at South Carolina 3 p.m. ESPNU — Penn St. at Kansas 4 p.m. ACCN — Clemson at Wake Forest SECN — Lipscomb at Missouri COLLEGE VOLLEYBALL (WOMEN’S) 3 p.m. ABC — NCAA Tournament: Wisconsin at Nebraska, Regional Final 8:30 p.m. ESPN — NCAA Tournament: Creighton at Penn St., Regional Final GOLF 4:30 a.m. GOLF — DP World Tour: The Alfred Dunhill Championship, Final Round, Leopard Creek Country Club, Malelane, South Africa 1 p.m. GOLF — LPGA/PGA Tour: The Grant Thornton Invitational, Final Round, Tiburon Golf Club and The Ritz-Carlton Naples, Naples, Fla. 2 p.m. GOLF — Korn Ferry/PGA Tour: The Q-School, Final Round, Sawgrass Country Club, Ponte Vedra Beach, Fla. NBC — LPGA/PGA Tour: The Grant Thornton Invitational, Final Round, Tiburon Golf Club and The Ritz-Carlton Naples, Naples, Fla. HORSE RACING 2:30 p.m. FS1 — NYRA: America’s Day at the Races NBA G-LEAGUE BASKETBALL 3 p.m. NBATV — Greensboro at Westchester NFL FOOTBALL 1 p.m. CBS — Regional Coverage: Kansas City at Cleveland, Baltimore at N.Y. Giants, Miami at Houston FOX — Regional Coverage: Cincinnati at Tennessee, Washington at New Orleans, Dallas at Carolina, N.Y. Jets at Jacksonville 4:25 p.m. CBS — Regional Coverage: Indianapolis at Denver, Buffalo at Detroit, New England at Arizona FOX — Regional Coverage: Pittsburgh at Philadelphia, Tampa Bay at L.A. Chargers 8:20 p.m. NBC — Green Bay at Seattle PEACOCK — Green Bay at Seattle NHL HOCKEY 3 p.m. NHLN — N.Y. Islanders at Chicago 6 p.m. NHLN — Vegas at Minnesota SKIING 4 p.m. NBC — FIS: Alpine World Cup, Beaver Creek, Colo. (Taped) SOCCER (MEN’S) 9 a.m. USA — Premier League: Crystal Palace at Brighton & Hove Albion 11:30 a.m. USA — Premier League: Manchester United at Manchester City 2 p.m. USA — Premier League: Brentford at Chelsea SOCCER (WOMEN’S) 7 p.m. CBSSN — Serie A: Sassuolo at Inter Milan (Taped) The Associated Press created this story using technology provided by Data Skrive TV listings provided by LiveSportsOnTV .
From Shopping to Advice From Warren BuffettThe Vicar & Archdeacon, Molete Archdeaconry of the Diocese of Ibadan, Ven. Olusegun Faleye has urged clergymen and Nigerian leaders in general, to learn to be humble, moderate, selfless and honest in their callings to encourage upcoming ones to live a holy life, thus encouraging the masses to live righteous lifestyles. In his sermon at the St. Anne’s Church, Molete, Ibadan on Sunday, in commemoration of the 70th Anniversary of the Ibadan Branch of the Nigerian Bar Association (NBA), Faleye, who deplored the socio-political and economic downturn in Nigeria, preached against impersonation and dishonesty, noting that whatever one becomes in life or accumulated on earth, is just temporal. The Christian lawyers among the congregants who were addressed in the sermon included: the Vice Chairman of the Ibadan NBA Branch, Mr Kehinde Oyewale, who led other lawyers including Prof. John Akintayo (Dean of the Faculty, of Law, University of Ibadan, who is also a former Chairman of the Branch); Pa Mathew Adepoju (NBA Patron); Mr Olayinka Esan (ex-Chairman); Mr Ademola Ademidun, Mr Yomi Aliu (SAN), and the Chief Registrar, Mrs. Ogunrin, who represented the Chief Judge of the State, Justice Iyabo Yerima, among others. The Vicar counselled leaders in general on the tenets and advantages of being honest, not being proud; and refraining from impersonation just like John the Baptist did in the Bible when he was applauded for many great things he did and so was asked by the people whether he was the Christ that was being expected. “He said, ‘I am not the Christ you are expecting. I am just His forerunner. As you are honouring me when Christ comes, you will see that I cannot even unbuckle His sandals”. Reading from the Book of John Chapter 1, verses 19-28, the Vicar said, “John just came to fulfil his role as forerunner, fore bearer and herald of Christ. He was the official messenger of Christ. Many of us who are Men of God arrogate to ourselves what we are not. Some even present themselves as Christ himself. “We should learn to be humble. Many of us Pastors, GOs, Reverends, Apostles, and Band bishops believe that younger ones must be suppressed and not allowed to grow if they perform well. “Whenever any miracle is done, be it real or fake, all radio stations must air it; all television stations must broadcast it. Some will even preach and when the congregants don’t clap for them, they compel them to clap. All this is profane. “John in the Bible tells us that all the things we run after in life are just temporal. So, as leaders, we should always live an exemplary life of honesty, humility, love, and transparency, while also encouraging others to live”, Faleye urged. The Vicar, therefore, hinted of some signs of end-time which everybody must be wary of, among them: “age of technology; the spread of the gospel; environmental challenges including climate change and even COVID-19; fake miracles, as well as, lovelessness”.
Denosumab biosimilar is a monoclonal antibody commercialized by & Co, with a leading Phase III program in Post Menopausal Osteoporosis. According to Globaldata, it is involved in 2 clinical trials, which were completed. Smarter leaders trust GlobalData The gold standard of business intelligence. The revenue for Denosumab biosimilar is expected to reach an annual total of $182 mn by 2040 globally based off GlobalData’s Revenue Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress. Denosumab biosimilar Overview Denosumab biosimilar (HLX-14) is under development for the treatment of giant cell tumor, bone metastases and postmenopausal women with osteoporosis at high risk for fracture. The drug candidate is a humanized monoclonal antibody. It is administered through subcutaneous route. The drug candidate acts by targeting receptor activator of nuclear factor kappa B ligand (RANKL). Organon & Co Overview & Co ( ) is a healthcare company. The company discovers and develops biosimilars and medicines. It provides medicines and solutions for various conditions including respiratory, cardiovascular, dermatology, non-opioid pain, women’s health and others. The company’s products include mometasone furoate inhalation powder, follitropin beta injection, alendronate sodium acetate injection, chorionic gonadotropin and others. distributes and sells its products through various channels including drug wholesalers and retailers, hospitals, government agencies and managed healthcare providers. It collaborates with pharmaceutical and biopharmaceutical businesses to market its products. It has operations in Europe North America, Asia Pacific, Latin America, Middle East, CIS and Africa. is headquartered in Jersey City, New Jersey, the US. The company reported revenues of (US Dollars) US$6,263 million for the fiscal year ended December 2023 (FY2023), an increase of 1.4% over FY2022. In FY2023, the company’s operating margin was 10.7%, compared to an operating margin of 18.2% in FY2022. In FY2023, the company recorded a net margin of 16.3%, compared to a net margin of 14.9% in FY2022. The company reported revenues of US$1,607 million for the second quarter ended June 2024, a decrease of 0.9% over the previous quarter. For a complete picture of Denosumab biosimilar’s valuation, From Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors. , the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company. The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s .CNN moves to dismiss North Carolina Lt. Gov Mark Robinson's defamation lawsuit
McCoy Global Inc. ( TSE:MCB – Get Free Report ) declared a quarterly dividend on Friday, November 8th, Zacks Dividends reports. Shareholders of record on Tuesday, December 31st will be paid a dividend of 0.02 per share on Wednesday, January 15th. This represents a $0.08 dividend on an annualized basis and a dividend yield of 2.81%. The ex-dividend date of this dividend is Tuesday, December 31st. McCoy Global Trading Up 2.5 % Shares of MCB stock opened at C$2.85 on Friday. The stock has a market cap of C$77.46 million, a P/E ratio of 9.19 and a beta of 0.58. McCoy Global has a 1 year low of C$1.81 and a 1 year high of C$3.84. The company has a current ratio of 3.13, a quick ratio of 1.26 and a debt-to-equity ratio of 6.50. The stock has a 50 day simple moving average of C$3.05 and a 200 day simple moving average of C$2.47. McCoy Global ( TSE:MCB – Get Free Report ) last released its earnings results on Friday, November 8th. The company reported C$0.02 earnings per share for the quarter. The firm had revenue of C$15.84 million during the quarter. McCoy Global had a return on equity of 15.52% and a net margin of 11.88%. On average, research analysts predict that McCoy Global will post 0.3003901 earnings per share for the current fiscal year. About McCoy Global McCoy Global Inc provides equipment and technologies to support tubular running operations that enhance wellbore integrity and assist with collecting critical data for the energy industry. The company’s products are used during the well construction phase for land and offshore wells during oil and gas exploration and development. Featured Articles Receive News & Ratings for McCoy Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McCoy Global and related companies with MarketBeat.com's FREE daily email newsletter .Jimmy Carter held a unique place in US politics: he was the oldest former president and a Nobel peace laureate, but his one term in office was forever tainted by his inability to end the 1979 Iran hostage crisis. Carter, who died Sunday at the age of 100, arguably wielded his greatest influence not during his 1977-1981 term in the White House, but in the decades following, when he served as a global mediator, rights activist and elder statesman. The Southern Democrat, who left 1600 Pennsylvania Avenue in January 1981 after a crushing election loss to Ronald Reagan, was perceived as naive and weak in the dog-eat-dog world of Washington politics. Even within his own party, the Georgia native with the broad toothy grin a "born-again" Christian who taught Sunday school well into his 90s was something of a persona non grata for a long time. But as the years passed, a more nuanced image of Carter emerged, one that took in his post-presidential activities and reassessed his achievements, like the brokering of a peace deal between Israel and Egypt. He placed a commitment to human rights and social justice at the core of his tenure as the 39th president of the United States. That dedication later served as the cornerstone of The Carter Center, which he founded in 1982 to pursue his vision of world diplomacy, earning broad international praise. Carter represented a new generation of Southern men who were more tolerant and progressive on issues of race. The former president who had been both a naval officer and a peanut farmer heartily embraced his roots. "I am a Southerner and an American," said Carter, a virtual unknown on the national political scene when he launched his presidential campaign ahead of the 1976 election. James Earl Carter Jr. the full name he rarely used was born on October 1, 1924 in the small farm town of Plains, Georgia, south of Atlanta the same town where he lived out his golden years. After seven years in the navy, where he worked on the nuclear submarine program and rose to the rank of lieutenant, he returned home to run the family peanut farm. But eventually, politics came calling. He served in Georgia's state senate and took over as governor in 1971. Only a few years later, his unlikely White House bid began. Carter arrived in Washington in January 1977, sworn in to head a country needing a strong leader to dispel the gloom left over from the Vietnam War, the Watergate scandal and a deep recession. For the first time since 1968, the Democrats controlled the White House and Congress, so hopes were high as Carter took office. He enjoyed a strong first two years, with high approval ratings. A shining moment of his term in office was the historic 1978 Camp David Accords signed by Israel's Menachem Begin and Egypt's Anwar Sadat, which ultimately led to a peace treaty the following year. Carter also established diplomatic relations with China following the rapprochement initiated by then-president Richard Nixon, and endorsed solar energy, even installing solar panels on the White House. But his administration hit numerous snags, the most serious being the Iran hostage crisis and the disastrous failed attempt to rescue the 52 captive Americans in 1980. His handling of the renewed oil crisis in 1979-1980 was also sharply criticized. Images of cars lined up at gas stations were long associated with his presidency. In the wake of Carter's defeat at the polls, the Democratic Party weathered a political storm 12 years of Republican presidents in Reagan and George H.W. Bush. Even now, few Democrats claim to be picking up Carter's mantle. In a biography published in 2010, historian Julian Zelizer, a professor at Princeton University, said Carter had fallen victim to "an extraordinarily difficult set of circumstances that would have challenged any president." But Carter bounced back in perhaps the most spectacular reinvention of any US leader and was often called America's "best ex-president." Carter founded his eponymous center in Atlanta and emerged as a prominent international mediator, tackling some of the most intransigent global dilemmas including North Korea and Bosnia in the 1990s. He monitored dozens of elections around the world, from Haiti to East Timor, and went to Cuba in 2002 for a historic meeting with then longtime communist leader Fidel Castro to prod him on human rights. Carter won a host of awards including the 2002 Nobel Peace Prize and the highest US civilian award, the Presidential Medal of Freedom. He won three Grammys for best spoken-word album, a category that included audiobooks. Carter maintained a busy schedule into his 90s. He and wife Rosalynn helped build houses for the charity Habitat for Humanity for decades. Rosalynn died in November 2023 at age 96. The couple had three sons and a daughter. In August 2015, Carter revealed he had cancer on his brain and was undergoing radiation treatment. At the time of his diagnosis, Carter said that while the presidency was the "pinnacle" of his political career, "life since the White House has been personally more gratifying." During a church service in November 2019 in Plains, Carter looked back with serenity, and a touch of humor at his battle with cancer. "I assumed, naturally, that I was going to die very quickly," he said. "I obviously prayed about it. I didn't ask God to let me live, but I asked God to give me a proper attitude toward death." "And I found that I was absolutely and completely at ease with death." bur-jca-mlm/sst/ec/bbk This article was generated from an automated news agency feed without modifications to text.NEW YORK , Dec. 15, 2024 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of ordinary shares of ASML Holding N.V. (NASDAQ: ASML) between January 24, 2024 and October 15, 2024 , both dates inclusive (the "Class Period"), of the important January 13, 2025 lead plaintiff deadline. So what: If you purchased ASML ordinary shares during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. What to do next: To join the ASML class action, go to https://rosenlegal.com/submit-form/?case_id=31159 or call Phillip Kim, Esq. at 866-767-3653 or email case@rosenlegal.com for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 13 , 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Details of the case: According to the lawsuit, during the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) the issues being faced by suppliers, like ASML, in the semiconductor industry were much more severe than defendants had indicated to investors; (2) the pace of recovery of sales in the semiconductor industry was much slower than defendants had publicly acknowledged; (3) defendants had created the false impression that they possessed reliable information pertaining to customer demand and anticipated growth, while also downplaying risk from macroeconomic and industry fluctuations, as well as stronger regulations restricting the export of semiconductor technology, including the products that ASML sells; and (4) as a result, defendants' statements about ASML's business, operations, and prospects lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the ASML class action, go to https://rosenlegal.com/submit-form/?case_id=31159 mailto: or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm , on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/ . Attorney Advertising. Prior results do not guarantee a similar outcome. ------------------------------- Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 case@rosenlegal.com www.rosenlegal.com View original content to download multimedia: https://www.prnewswire.com/news-releases/asml-deadline-asml-investors-with-losses-in-excess-of-100k-have-opportunity-to-lead-asml-holding-nv-securities-fraud-lawsuit-302331928.html SOURCE THE ROSEN LAW FIRM, P. A.